Obstetric medicine · 2025
Efficacy and safety of casirivimab/imdevimab (REGEN-COV) in pregnant individuals with COVID-19: Literature review and insights from the COVID-19 International Drug Pregnancy Registry.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wyszynski Diego F, Yau Vincent, Keebler Daniel, Renz Cheryl, Ives Jane, Fitzgibbon Andrew, Shulman Lee P
Аннотация
INTRODUCTION: Casirivimab/imdevimab (CAS/IMD) comprises two monoclonal antibodies that neutralize SARS-CoV-2. Pregnant individuals were excluded from initial trials, limiting safety data.
METHODS: The COVID-19 International Drug Pregnancy Registry enrolled 53 pregnant women treated with CAS/IMD, with 34 live births.
RESULTS: No safety concerns were identified.
DISCUSSION AND CONCLUSIONS: The findings of the COVID-PR study support the safety of CAS/IMD during pregnancy, adding to the growing body of evidence on COVID-19 treatments for this population. The available literature shows that CAS/IMD is effective in preventing the progression to severe COVID-19 in pregnant individuals. The drugs are well-tolerated, and there is no compelling evidence of adverse maternal or neonatal outcomes. The results from the COVID-PR study are consistent with those of the broader literature.
METHODS: The COVID-19 International Drug Pregnancy Registry enrolled 53 pregnant women treated with CAS/IMD, with 34 live births.
RESULTS: No safety concerns were identified.
DISCUSSION AND CONCLUSIONS: The findings of the COVID-PR study support the safety of CAS/IMD during pregnancy, adding to the growing body of evidence on COVID-19 treatments for this population. The available literature shows that CAS/IMD is effective in preventing the progression to severe COVID-19 in pregnant individuals. The drugs are well-tolerated, and there is no compelling evidence of adverse maternal or neonatal outcomes. The results from the COVID-PR study are consistent with those of the broader literature.